A Pilot Study to Investigate the Role of Thymidylate Synthase as a Marker of Prognosis for Neoadjuvant Chemotherapy in Gastric and Gastro-Oesophageal Junction Adenocarcinoma

Table 3

Univariate analysis of clinicopathological factors.

Characteristic		Overall survival		Cancer-specific survival
		HR (95% CI)	𝑃	HR (95% CI)	𝑃
Gender	Male versus female	1.13 (0.37–3.47)	0.82	0.80 (0.21–3.04)	0.75
T stage	0/1/2 versus 3/4	0.95 (0.37–2.46)	0.91	1.08 (0.31–3.82)	0.90
N stage	Positive versus negative	2.36 (1.52–3.46)	0.02	3.95 (1.04–6.82)	0.04
Lymphatic invasion	Present versus absent	1.18 (0.38–3.66)	0.77	1.03 (0.27–3.96)	0.96
Vascular invasion	Present versus absent	2.91 (1.02–4.03)	0.04	1.55 (0.33–7.31)	0.35
CRM	Positive versus negative	0.76 (0.42–3.32)	0.76	1.71 (0.55–5.26)	0.14
Differentiation	Well/moderate versus poor	1.08 (0.42–2.82)	0.86	0.85 (0.28–2.56)	0.64
TS	Negative versus positive	1.32 (0.36–2.56)	0.81	1.27 (0.29–1.92)	0.76